While Johnson & Johnson isn't the first to secure FDA approval for an FcRn-blocking antibody in myasthenia gravis, the New ...

Charles Barkley is going on the offense after seeing his weight rebound. | Charles Barkley is going on the offense after ...

Despite formidable competition in the growing transthyretin amyloid cardiomyopathy (ATTR-CM) market, a strong early launch ...

Over the years, a host of large drugmakers have inked settlements with the federal authorities to resolve allegations that ...

AstraZeneca has come up short in another phase 3 trial of the AKT inhibitor Truqap, raising more questions about the ...

Once again, several members of Congress have come together to call for an end to the tax deductions that drugmakers receive ...

After consecutive setbacks at the FDA, Regeneron's string of recent troubles with its Eylea franchise is continuing to pull ...